Research programme: Burkholderia infections vaccine - Bavarian Nordic

Drug Profile

Research programme: Burkholderia infections vaccine - Bavarian Nordic

Latest Information Update: 27 Feb 2014

Price : $50

At a glance

  • Originator Bavarian Nordic
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Burkholderia infections

Most Recent Events

  • 21 Feb 2014 Preclinical trials in Burkholderia infections in Denmark (Parenteral)
  • 21 Feb 2014 Bavarian Nordic receives contract from Defense Threat Reduction Agency (DTRA) of the US Department of Defense for Burkholderia infections vaccine development in
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top